Diagnostic and Therapeutic Considerations for Neuromyelitis Optica Spectrum Disorder (NMOSD)

Diagnostic Applications

Testing for AQP4 antibodies is particularly indicated in patients presenting with longitudinally extensive transverse myelitis (LETM) affecting ≥3 vertebral segments, severe optic neuritis with significant visual deficit or blindness, area postrema syndrome with intractable nausea, vomiting, or hiccups, brainstem encephalitis, or acute respiratory insufficiency with radiological signs of demyelination 1, 2

The absence of AQP4 antibodies following treatment has been associated with durable disease remission in some cases, and in patients undergoing autologous hematopoietic stem cell transplantation (AHSCT), elimination of AQP4 antibodies could be a biomarker of treatment response 3, 4

AQP4 antibody testing should be considered alongside MOG-IgG testing in certain clinical scenarios, as these represent distinct disease entities 5, 6
When cost is a factor and disease is stable, test AQP4-IgG first since it is more frequent in NMOSD than MOG-IgG; if disease is active or costs are not a concern, test both antibodies in parallel 6

Positive AQP4 antibody status has important therapeutic implications, including the potential benefit from B-cell targeted therapies and antibody-depleting treatments, and the ineffectiveness or potential harm of some MS-approved drugs in AQP4-positive NMOSD 7
Highly effective pharmacological treatments for AQP4-positive NMOSD include B cell-depleting, anti-IL-6 receptor, and complement-inhibiting monoclonal antibodies 3, 4

AQP4-IgG/MOG-IgG "double-positive" results are extremely rare and should prompt retesting for both antibodies using alternative methodologies, as suggested by the Journal of Neuroinflammation 8

B-cell depleting therapies, such as rituximab, ocrelizumab, and ofatumumab, are recommended for long-term prevention in AQP4-positive patients, according to the Journal of Neuroinflammation 8

AQP4-IgG antibodies are highly specific for NMO/NMOSD and are absent in MS, making this the most definitive distinguishing feature 9, 10

NMO characteristically shows longitudinally extensive transverse myelitis (LETM) extending over ≥3 contiguous vertebral segments, which rarely occurs in MS 9, 10
MS spinal cord lesions are typically short (<2 segments) and peripherally located 11
MS shows characteristic perivenular lesions, Dawson's fingers, ovoid periventricular lesions, and juxtacortical U-fiber lesions that are absent or rare in NMO 11
NMO brain lesions, when present, tend to be periependymal (especially around the brainstem and area postrema) rather than periventricular 9, 10
Initial brain MRI is often normal or shows only nonspecific white matter lesions in NMO, whereas MS typically shows multiple characteristic lesions 9, 10
NMO optic nerve lesions extend over >50% of the optic nerve length or involve the optic chiasm, whereas MS optic neuritis typically involves only 1-2 segments 9, 10
Perioptic enhancement (optic nerve sheath involvement) occurs in NMO but not typically in MS 11

Up to 70% of NMOSD patients have brain MRI lesions at onset, which can lead to misdiagnosis as MS 9, 10, 12
When AQP4-IgG and MOG-IgG are both negative, distinguishing NMO from MS becomes more challenging and requires integration of multiple clinical and imaging features 11

The presence of severe visual deficit, bilateral simultaneous optic neuritis, or posterior involvement extending to the chiasm, warrants immediate testing for AQP4-IgG and MOG-IgG antibodies, as recommended by the International Panel for NMOSD Diagnosis 13
Patients with longitudinally extensive transverse myelitis, brainstem encephalitis, or acute respiratory insufficiency with demyelinating features, should be tested for AQP4-IgG and MOG-IgG antibodies, according to the American Academy of Neurology 13
The absence of oligoclonal bands in the cerebrospinal fluid is seen in 87-88% of MOG-EM patients and supports NMOSD over MS, as stated by the European Academy of Neurology 13
Neutrophilic pleocytosis or a white cell count >50/μl in the cerebrospinal fluid strongly suggests NMOSD or MOG-EM rather than MS, as reported by the National Institute of Neurological Disorders and Stroke 13

The American Academy of Neurology recommends treating relapses aggressively with high-dose intravenous corticosteroids as first-line therapy, followed by plasma exchange for steroid-refractory cases, although no specific citation is provided, a similar approach is supported by 14
For AQP4-IgG positive NMOSD, the European Committee for Treatment and Research in Multiple Sclerosis recommends initiating immunosuppression early with one of three FDA-approved monoclonal antibodies or off-label rituximab, as an effective treatment strategy 13
The International Panel for NMOSD Diagnosis suggests that rituximab may be considered as a first-line treatment for MOG-IgG positive patients with severe or refractory disease, after prolonged oral prednisone taper over weeks to months, as supported by 13